Cargando…

Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates

Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine,...

Descripción completa

Detalles Bibliográficos
Autores principales: Chan, Christina, Martin, Philip, Liptrott, Neill J., Siccardi, Marco, Almond, Lisa, Owen, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625163/
https://www.ncbi.nlm.nih.gov/pubmed/28971619
http://dx.doi.org/10.1002/prp2.359
_version_ 1783268348969091072
author Chan, Christina
Martin, Philip
Liptrott, Neill J.
Siccardi, Marco
Almond, Lisa
Owen, Andrew
author_facet Chan, Christina
Martin, Philip
Liptrott, Neill J.
Siccardi, Marco
Almond, Lisa
Owen, Andrew
author_sort Chan, Christina
collection PubMed
description Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine, and puromycin were assessed individually, and in two‐, three‐, and four‐drug combinations for protein synthesis inhibition (IC (50)) and cytotoxicity (CC (50)) over 72 h. Experiments were conducted in HepG2 cells and primary rat hepatocytes (PRH). IC (50) for actinomycin D, cycloheximide, emetine, and puromycin were 39 ± 7.4, 6600 ± 2500, 2200 ± 1400, and 1600 ± 1200 nmol/L; with corresponding CC (50) values of 6.2 ± 7.3, 570 ± 510, 81 ± 9, and 1300 ± 64 nmol/L, respectively, in HepG2 cells. The IC (50) were 1.7 ± 1.8, 290 ± 90, 620 ± 920, and 2000 ± 2000 nmol/L, with corresponding CC (50) values of 0.98 ± 1.8, 680 ± 1300, 180 ± 700, and 1600 ± 1000 (SD) nmol/L, respectively, in PRH. CC (50) were also lower than the IC (50) for all drug combinations in HepG2 cells. These data indicate that using pharmacological interference is inappropriate for measuring protein degradation over a protracted period, because inhibitory effects cannot be extricated from cytotoxicity.
format Online
Article
Text
id pubmed-5625163
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-56251632017-10-04 Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates Chan, Christina Martin, Philip Liptrott, Neill J. Siccardi, Marco Almond, Lisa Owen, Andrew Pharmacol Res Perspect Original Articles Protein synthesis inhibitors are commonly used for measuring protein degradation rates, but may cause cytotoxicity via direct or indirect mechanisms. This study aimed to identify concentrations providing optimal inhibition in the absence of overt cytotoxicity. Actinomycin D, cycloheximide, emetine, and puromycin were assessed individually, and in two‐, three‐, and four‐drug combinations for protein synthesis inhibition (IC (50)) and cytotoxicity (CC (50)) over 72 h. Experiments were conducted in HepG2 cells and primary rat hepatocytes (PRH). IC (50) for actinomycin D, cycloheximide, emetine, and puromycin were 39 ± 7.4, 6600 ± 2500, 2200 ± 1400, and 1600 ± 1200 nmol/L; with corresponding CC (50) values of 6.2 ± 7.3, 570 ± 510, 81 ± 9, and 1300 ± 64 nmol/L, respectively, in HepG2 cells. The IC (50) were 1.7 ± 1.8, 290 ± 90, 620 ± 920, and 2000 ± 2000 nmol/L, with corresponding CC (50) values of 0.98 ± 1.8, 680 ± 1300, 180 ± 700, and 1600 ± 1000 (SD) nmol/L, respectively, in PRH. CC (50) were also lower than the IC (50) for all drug combinations in HepG2 cells. These data indicate that using pharmacological interference is inappropriate for measuring protein degradation over a protracted period, because inhibitory effects cannot be extricated from cytotoxicity. John Wiley and Sons Inc. 2017-09-29 /pmc/articles/PMC5625163/ /pubmed/28971619 http://dx.doi.org/10.1002/prp2.359 Text en © 2017 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Chan, Christina
Martin, Philip
Liptrott, Neill J.
Siccardi, Marco
Almond, Lisa
Owen, Andrew
Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title_full Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title_fullStr Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title_full_unstemmed Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title_short Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
title_sort incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625163/
https://www.ncbi.nlm.nih.gov/pubmed/28971619
http://dx.doi.org/10.1002/prp2.359
work_keys_str_mv AT chanchristina incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates
AT martinphilip incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates
AT liptrottneillj incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates
AT siccardimarco incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates
AT almondlisa incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates
AT owenandrew incompatibilityofchemicalproteinsynthesisinhibitorswithaccuratemeasurementofextendedproteindegradationrates